This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Karen Wen
Chief Strategy and Product Development Officer at GenomeFrontier Therapeutics, Inc., Taiwan


Karen Wen is a pioneer in the field of biological product development specialized in process development and PIC/S GMP production including peptide, proteins, monoclonal antibodies, DNA vaccine and antibody-cell conjugate product and is expanding her professionals in the area of gene and cellular therapy.  In this presentation, Karen will share the company’s proprietary technology, a non-viral system for gene(s) delivery in the CAR-T therapy.  This high- quality CAR+ technology is a disruptive innovation and expected to provide the better opportunity for larger gene loading capacity for solid tumor treatment.   This convivence and cost effectiveness of this non-viral gene delivery system would lead the gene and cellular therapy into the new era.

Agenda Sessions

  • Novel Non-Viral Vector Based CAR-T Platform Development and Progress Update